Neurology
Teva announces positive results from trial of AJOVY for migraine
December 5, 2025Research and Development Neurology, Teva, migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its treatment for chronic (CM) and …
Rare and severe epilepsies – current treatments and advance therapeutics
August 29, 2025Medical Communications, Research and Development Neurology, UCB, epilepsy, epilepsy treatment, rare epilepsies
The current forms of immunotherapy, how T cell therapy works and what the future holds
Epilepsy Research Institute opens 2025-26 grant round with new awards
August 21, 2025Medical Communications, Research and Development Neurology, epilepsy, funding programme, medical research
The Epilepsy Research Institute has opened its 2025-26 Grant Round, offering a wide range of funding opportunities designed to support …
Five Facts about epilepsy
August 21, 2025Medical Communications Five Facts, Neurology, epilepsy, neurological condition, seizures
1 Epilepsy occurs when the normal electrical activity in the brain changes. For many, the cause is unclear, but genes …
FDA decision on Neurizon’s ALS therapy delayed until October
August 18, 2025Medical Communications Coya Therapeutics, Neurizon, Neurology, US Food and Drug Administration, amyotrophic lateral sclerosis
Neurizon Therapeutics has announced that the US Food and Drug Administration (FDA) will delay its decision on the company’s Clinical …
PhotoPharmics expands Parkinson’s Trial into further US states
August 14, 2025Research and Development Neurology, PhotoPharmics, clinical trial, neurodegenerative disorders
US-based PhotoPharmics, has expanded enrollment in its Light for PD clinical trial beyond its original 300 participants, opening new sites …
PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit
August 7, 2025Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases
French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
August 6, 2025Mergers and Acquisitions Alzheimer's disease, Corporate, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology company specialising in neurodegenerative diseases. …
Lilly’s drug for early Alzheimer’s shows promising results
August 6, 2025Medical Communications, Research and Development Alzheimer's, Eli Lilly, Neurology, dementia
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase 3 study, showing that Kisunla …
Roche receives CE Mark for blood test to help rule out Alzheimer’s
July 30, 2025Research and Development Alzheimer's disease, CE Mark approval, Eli Lilly, Neurology, Roche
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in vitro diagnostic regulation-certified blood-based diagnostic …
Relief Therapeutics to merge with NeuroX to create AI-driven neurohealth company
July 29, 2025Mergers and Acquisitions, Research and Development AI, Corporate, MindMaze, Neurology, Relief Therapeutics, neurological conditions
Relief Therapeutics has announced that it will combine with NeuroX Group, the successor to digital neurotherapeutics company MindMaze. The transaction …
Neuraxpharm appoints Avendran Naidu as head of commercial upon launch of Australian affiliate
July 28, 2025Manufacturing and Production, Research and Development Neuraxpharm, Neuraxpharm Australia, Neurology, central nervous system, multiple sclerosis
Neuraxpharm Group has announced the launch of Neuraxpharm Australia, furthering its global expansion beyond Europe and into key international markets. …
MetP Pharma releases positive data on intranasal semaglutide administration
July 22, 2025Research and Development Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …
Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse
July 18, 2025Medical Communications, Research and Development CAPLYTA, Johnson & Johnson, Neurology, US Food and Drug Administration, neuroscience, new drug application, schizophrenia
Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Caplyta …
Biogen and Stoke report positive results for Dravet syndrome drug
July 17, 2025Research and Development Biogen, Dravet Syndrome, Neurology, Stoke Therapeutics, epilepsy, rare diseases
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which is being developed for Dravet …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
